In application of the Luxembourg law dated 17 December 2021 extending the measures initially introduced by the Grand Ducal
Regulation of 20 March 2020, enacted into law by the Luxembourg law dated 20 June 2020 and prolonged by the Luxembourg law
dated 23 September 2020 in relation with the holding of meetings in companies and other legal entities in light of the exceptional
circumstances surrounding the COVID-19 (the Emergency Legislation) and notwithstanding any contrary provisions in the articles of association of the Company (the Articles), the Company will not hold a physical meeting.
Shareholders may exercise their rights at the meeting exclusively by appointing a special proxyholder (please refer to item
V. (Participation)).
III |
Total amount of shares
Total amount of shares on the date of the convening of the meeting, the Company’s subscribed share capital equals EUR 2,564,535.97,
represented by 34,193,808 shares without nominal value, all of which are fully paid up. Each share carries one vote. The total
number of voting rights is therefore 34,193,808.
|
IV |
Available information and documentation
The following information is available on the Company’s website under
www.corestate-capital.com |
in the segment “Shareholders” > “General Meeting” and at the Company’s registered office in Luxembourg (as specified in the
header), as of the day of the publication of this convening notice:
(i) |
full text of any document to be made available by the Company at the meeting, including draft resolutions in relation to the
above agenda items to be adopted at the Meeting and related documents;
|
(ii) |
this convening notice;
|
(iii) |
the Board Report;
|
(iv) |
the total number of shares and attached voting rights issued by the Company as of the date of publication of this convening
notice;
|
(v) |
the Proxy Form as further mentioned below; and
|
(vi) |
the Record Date Attestation form as further mentioned below.
|
|
V |
Participation
The participation at the meeting and the exercise of voting rights attached to the shares held by a shareholder is determined
in relation to the number of shares held by each shareholder at 24:00 (CET) on the day falling fourteen (14) days before the
general meeting (20 October 2022) (the Record Date). Only persons who are shareholders on the Record Date will have the right to participate and vote in the meeting.
No later than on the Record Date the shareholders shall communicate their intention to participate at the meeting by the Record
Date via email or by post to:
Corestate Capital Holding S.A. c/o Computershare Operations Center 80249 München Germany E-Mail: anmeldestelle@computershare.de
Additionally, shareholders must produce an attestation from their depository bank stating the number of shares held by the
shareholder on the Record Date in order to be permitted to exercise their rights at the meeting (the Record Date Attestation).
In accordance with the Emergency Legislation, the Company will not hold a physical meeting. Shareholders may exercise their
rights at the meeting by appointing in writing Mr Patrick Ehrich or such other proxy as they may chose, as a special proxyholder
based on a duly completed, dated and signed special proxy form (the Proxy Form). Any proxy appointed by a shareholder other than Mr Patrick Ehrich (or its subdelegate) will be required to cast their vote
by correspondence by completing the voting instructions as included in the annex to the Proxy Form.
In order for votes pursuant to a Proxy Form to be considered, the Company must be provided with a Record Date Attestation
relating to the relevant shareholder.
The Record Date Attestation and the Proxy Form must be received by the Company on 28 October 2022 at 11:59 p.m. (CET) at the
latest at the following address:
Corestate Capital Holding S.A. c/o Computershare Operations Center 80249 München Germany E-Mail: anmeldestelle@computershare.de
Exercise of voting rights of shares in connection with Proxy Forms received after such date will not be possible.
The Proxy Forms and Record Date Attestations are available on the Company’s website under
www.corestate-capital.com |
in the segment “Shareholders” > “General Meeting”.
|
VI |
Ability to ask questions before the meeting
In accordance with the Emergency Legislation, no physical meeting will be organised and any shareholder questions must thus
be addressed in advance of the meeting.
Shareholders’ questions in relation with the agenda must be sent (by post or e-mail) to the contact information mentioned
under item V. (Participation) above and received by the Company on 28 October 2022 at 11:59 p.m. (CET) at the latest.
A Record Date Attestation must be attached to such questions to allow the Company to proceed with a satisfactory identification
of the relevant shareholder. The answers to these questions will be provided during a conference call to be held on the date
of the meeting. The precise time and joining instructions for such conference call will be made available to registered shareholders
prior to the meeting. Please note that shareholders can dial into such conference call but will only be able to hear and will
not be allowed to speak.
|
VII |
Additional important information for shareholders
Shareholders are hereby informed that the exercise of voting rights is exclusively reserved to such persons that were shareholders
on the Record Date (respectively the special proxyholder duly appointed by them). Transfer of shares after the Record Date
is possible subject to usual transfer limitations, as applicable. However, any transferee having become owner of shares after
the Record Date has no right to vote at the meeting.
One or more shareholder(s) representing at least 5% of the Company’s share capital may request the addition of items to the
agenda of the meeting or table draft resolutions for items included or to be included on the agenda of the meeting by sending
such requests (by post or e-mail) at the latest on 12 October 2022 at 11:59 p.m. (CET) to the contact information mentioned
under item V. (Participation) above. Such request will only be accepted by the Company provided it includes (i) the wording
of the agenda point, (ii) the wording of a proposed resolution pertaining to such agenda point or a justification, and (iii)
an e-mail address or a postal address to which the Company may correspond and confirm receipt of the request. The Company
shall publish a revised agenda no later than the fifteenth day before the date of the meeting (i.e. 19 October 2022).
If you have questions regarding the meeting feel free to send us an e-mail at
anmeldestelle@computershare.de |
or give us a call on the following number: +49 89 30903 6330.
|
VIII |
Data Protection Notice
Since the European Data Protection Act came into effect, data protection laws and regulations apply throughout Europe from
25 May 2018 onwards. The protection of your data and the legally compliant processing of your data have a high priority for
us. In our data protection notice for shareholders, we have summarized all information regarding the processing of personal
data of our shareholders in a clear and structured way.
The data protection notice for shareholders can be retrieved and is available for viewing and downloading on the Company’s
website under www.corestate-capital.com in the segment “Shareholders” > “General Meeting”.
The direct link is: https://corestate-capital.com/data-protection-agm-2022.pdf
|
SCHEDULE 1 TO THE CONVENING NOTICE – EGM 3 NOVEMBER 2022
Proposed new wording of article 5.5 of the Articles:
“5.5 Authorisation for the Management Board to increase the share capital
(a) Size of the authorisation
The authorised capital of the Company is set at fifteen million Euro (EUR 15,000,000) represented by up to two hundred million
(200,000,000) shares, each without nominal value.
(b) Terms of the authorisation
The Management Board is authorised, during a period starting on the date of the last extraordinary general shareholders’ meeting
of the Company having modified the authorised capital and expiring on the fifth anniversary of such date (the Period), to increase the current share capital by an additional share capital of fifteen million Euro (EUR 15,000,000), represented
by a maximum of two hundred million (200,000,000) shares, in whole or in part from time to time, (i) by way of issuance of
shares in consideration for a payment in cash, (ii) by way of issuance of shares in consideration for a payment in kind and
(iii) by way of capitalisation of distributable profits and reserves, including share premium and capital surplus, with or
without an issuance of new shares.
Subject to the prior consent matters as set out under Article 15 below, the Management Board is authorised to determine the
terms and conditions attaching to any subscription and issuance of shares pursuant to the authority granted under this Article
5.5, including by setting the time and place of the issue or the successive issues of shares, the issue price, with or without
a share premium, and the terms and conditions of payment for the shares under any documents and agreements including, without
limitation, convertible loans, option agreements or stock option plans.
The Management Board is authorised to (i) during the Period, (a) issue convertible bonds, or any other convertible debt instruments,
bonds carrying subscription rights or any other instruments entitling their holders to subscribe for or be allocated with
shares, such as, without limitation, warrants (the Instruments), and (b) issue shares subject to and effective as of the exercise of the rights attached to the Instruments, until, with
respect to both items (a) and (b), the amount of increased share capital that would be reached as a result of the exercise
of the rights attached to the Instruments is equal to the authorised share capital, and (ii) issue shares pursuant to the
exercise of the rights attached to the Instruments until the amount of increased share capital resulting from such issuance
of shares is equal to the authorised share capital, at any time, whether or not during the Period; provided that the Instruments
are issued during the Period. The shares to be issued following the exercise of the rights attached to the Instruments may
be carried out by a payment in cash, a payment in kind or a capitalisation of distributable profits and reserves, including
share premium and capital surplus.
The Management Board is authorised to determine the terms and conditions of the Instruments, including the price, the interest
rate, the exercise rate, conversion rate or the exchange rate, and the repayment conditions, and to issue such Instruments.
(c) Authorisation to cancel or limit the pre-emptive rights
The Management Board may, during the Period, cancel or limit the pre-emptive rights of the shareholders set out in the Companies
Act, as reflected in Article 5.3, in connection with an issue of new shares and Instruments under the authorisation set out
in this Article 5.5.
(d) Free Shares
The Management Board is authorised to carry out (i) a free allocation of new Shares, within the limits of the Company’s authorised
share capital as detailed at Articles 5.5(a) and (b) above, such shares being paid up by way of capitalisation of distributable
profits and reserves, including share premium and capital surplus and (ii) an allocation of existing Shares for no consideration,
in each case to those persons to whom such free allocation or issuance is permitted in the Company Law. The Board is further
authorised to set the terms and conditions of such allocation or issuance.
(e) Recording of capital increases in the Articles
Article 5 of the Articles shall be amended so as to reflect each increase in share capital pursuant to the use of the authorisation
granted to the Management Board under this Article 5 and the Management Board shall take or authorise any person to take any
necessary steps for the purpose of the recording of such increase and the consequential amendments to the Articles before
a notary.”